483
Corixa Corporation d.b.a. GlaxoSmithKlineCorixa Corporation d.b.a. GlaxoSmithKline – FDA 483, Mar 4, 2022
Record Details
Corixa Corporation d.b.a. GlaxoSmithKline in Marietta, PA, a drug manufacturer, received a Form 483 with two observations. The inspection found deficiencies in packaging facility line clearance procedures, resulting in materials from previous batches remaining on the line. Additionally, investigations into batch failures lacked complete conclusions and follow-up, specifically regarding the assessment of impacted products.
View Company Profile
ID · 66b7f6dc-5234-4cb2-9241-fd571a6609fb
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.